Maintaining Data Integrity During Sample Transfers in Clinical Trials

Introduction: The Critical Role of Data Integrity in Chain of Custody

Maintaining data integrity during clinical sample transfers is a regulatory imperative. Whether moving biological specimens between sites, labs, or third-party vendors, every handover must be documented, secure, and traceable. The FDA and EMA both expect that all data related to the transfer, condition, and custody of clinical samples uphold ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, and Available).

Chain of custody (CoC) logs serve as the primary documentation tool for sample transfers. However, without robust procedures, data errors can compromise sample validity and study outcomes. This article outlines practical steps and tools to ensure data integrity throughout the sample transfer process and highlights key regulatory touchpoints.

Regulatory References for Sample Transfer Integrity

Global regulators outline several requirements related to custody and data during sample transfers:

• FDA Guidance on Data Integrity (2018): Emphasizes secure and traceable data during critical processes like sample movement.
• EMA Reflection Paper on GCP Compliance: Requires complete traceability for biological samples from collection to analysis.
• ICH E6(R2): Calls for documentation controls to ensure integrity throughout the data lifecycle.

Key Components of Data Integrity in Sample Transfers

Every transfer must include the following data components to be considered compliant:

• Unique sample identifier (linked to subject and protocol)
• Date and time of handover with accurate timestamps
• Sender and receiver names with signatures or electronic approvals
• Condition of sample at time of transfer (e.g., frozen, ambient)
• Packaging verification and any temperature-control measures
• Courier details (if applicable) with tracking number
• Evidence of receipt by designated personnel at destination

Case Study 1: Break in Chain of Custody Audit Trail

During a Phase II diabetes trial, the EMA observed that the chain of custody log lacked receiver confirmation for a set of urine samples transferred to a central lab. Although the courier manifest was complete, the absence of site-to-courier signature created a break in the audit trail.

CAPA Actions:

• Updated SOP to mandate dual confirmation (site and courier)
• Introduced timestamped QR-based handover forms
• Developed automated audit alerts for incomplete logs

Case Study 2: Data Tampering Risk in Manual Entry

An FDA inspection revealed that paper-based chain of custody logs were editable post-shipment, with no log of who altered the record. Although there was no proven tampering, the lack of access control posed a data integrity risk.

CAPA Implementation:

• Switched to secure electronic custody system (eCoC)
• Configured role-based access for data entry and review
• Enabled audit trails with user ID and timestamps

Table: Data Integrity Risks and Preventive Controls

Tools to Support Data Integrity in Custody Documentation

Many sponsors and CROs are turning to validated software platforms to manage custody documentation, including:

• eCoC systems: Secure digital logs with real-time access and audit trail
• Courier apps: Handheld tools for scanning sample IDs and capturing GPS/time/location data
• Sample tracking dashboards: Centralized overview of sample movement and custody status

External Resource

For additional guidance on documentation and chain of custody, refer to Japan’s Clinical Trial Registry Portal.

Conclusion

In today’s decentralized and global trial landscape, ensuring data integrity in sample transfers is non-negotiable. A robust CoC system, supported by electronic documentation, secure handovers, and preventive controls, helps organizations meet FDA and EMA expectations while protecting sample validity. Case studies consistently show that even minor gaps in custody data can lead to major regulatory findings. Proactive SOPs and strong CAPA frameworks are key to maintaining compliance and readiness.

Chain of Custody in Sample Transport – Audit-Proof Guide

Introduction: Why Chain of Custody Matters in Clinical Trials

The movement of clinical trial biospecimens—from site to central lab or biorepository—must be fully traceable to protect data integrity, subject safety, and regulatory compliance. The “chain of custody” ensures that each transfer of a biological sample is documented, authorized, and verifiable, minimizing the risk of tampering, loss, or misidentification.

Both FDA and EMA inspectors evaluate sample transport documentation as part of inspection readiness. An incomplete or non-compliant chain of custody log is considered a major finding and may compromise trial outcomes.

Regulatory Expectations for Sample Chain of Custody

According to ICH GCP E6(R2), all sample handling must preserve the identity and integrity of the sample from collection to analysis. Key compliance factors include:

• Uniquely identifiable sample linked to subject ID and visit
• Documented custody transfers including date, time, and signatory
• Reconciliation of sample receipt with manifest at central lab
• Temperature log maintenance for temperature-controlled samples
• Secure transport with tamper-evident seals

SOP Requirements for Chain of Custody

The SOP governing biospecimen transport must clearly define:

• Roles and responsibilities of site staff, couriers, and central lab personnel
• Log formats and required data fields for custody transfer
• Criteria for rejecting samples with broken seals or missing documentation
• Corrective action process for custody deviations
• Document retention and integration into the eTMF

Table: Required Fields in Chain of Custody Logs

Case Study: FDA Inspection – Custody Gap Finding

During an FDA inspection of a metabolic disorder trial, the agency cited a major deviation where 13 samples shipped from the site lacked documented handover from the principal investigator to the courier. The courier logs only had delivery timestamps, but no corresponding pick-up records.

CAPA Actions Taken:

• Revised SOP to mandate dual sign-off at site departure
• Mandatory use of a courier custody form with preprinted sample IDs
• Retrospective reconciliation between site log, manifest, and lab receipt log

Best Practices for Maintaining Custody Integrity

To ensure regulatory compliance and minimize risk:

• Use tamper-evident packaging with serial number linkage
• Implement real-time scan-based tracking systems with GPS for temperature-sensitive shipments
• Ensure sample packaging includes printed manifest and seal verification stickers
• Request courier service logs with timestamps and names
• Verify central lab reconciliation reports match site manifest

Training and CAPA Readiness

All clinical staff must be trained on proper documentation procedures. Training must include:

• Mock transport scenarios with logbook practice
• Temperature log handling and verification process
• Error correction procedures in case of documentation mistakes
• Response plans for lost or compromised samples

CAPA must be initiated for any gaps in custody documentation and include root cause analysis and trend monitoring.

External Reference

More guidance on secure sample transport is available via the Australian New Zealand Clinical Trials Registry which outlines region-specific biosample logistics best practices.

Conclusion

A robust and auditable chain of custody process is not only a regulatory expectation but a cornerstone of clinical trial credibility. Sponsors and sites must invest in clear SOPs, validated custody documentation, and staff training to prevent sample mishandling, data loss, and inspection findings. Whether using manual forms or integrated eSystems, maintaining a continuous, gap-free custody trail is essential to uphold trust in trial outcomes.